JAGX

Jaguar Health, Inc. Common Stock NASDAQ Capital Market
$1.66
Open: $1.65 High: $1.73 Low: $1.62 Close: $1.662
Range: 2021-06-23 - 2021-06-24
Volume: 7,083,238
Market: Open
Powered by Finage Stock APIDelayed data
JAGX
Jaguar Health, Inc. Common Stock 201 Mission Street San Francisco CA, 94105 http://www.jaguaranimalhealth.com
Jaguar Health Inc is an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses.
  • CEO: Lisa A Conte
  • Employees: 36
  • Sector: Healthcare
  • Industry: Biotechnology
JAGX News
Latest news about the JAGX
  • Jaguar Health Set to Join Russell Microcap Index

    Jaguar kicks off educational awareness contest about medicinal plantsSAN FRANCISCO, CA / ACCESSWIRE / June 23, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Jaguar is set to join the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, 2021, according to a preliminary list of additions posted by FTSE Russell.

    View More →
  • Is Jaguar Health, Inc. (JAGX) A Good Stock To Buy?

    With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second quarter of 2021. One of these stocks was Jaguar Health, Inc. (NASDAQ:JAGX). Is JAGX a good […]

    View More →
  • Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, July 9, 2021 and Encourages All Shareholders to Vote

    Based on a preliminary review of votes cast, over 76% have voted in favor of Proposals 2, 3, 4 & 6 Meeting scheduled to reconvene July 9, 2021 at 8:30 AM Pacific Standard Time to provide time to reach quorumSAN FRANSICO, CA / ACCESSWIRE / June 11, 2021 / Jaguar Health, Inc. (Nasdaq:JAGX) ('Jaguar' or the 'Company') today announced that it has adjourned its Annual Meeting of Stockholders held on May 13, 2021 (the "Annual Meeting") for a second time due to a lack of quorum.

    View More →
  • Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN FRANCISCO, CA / ACCESSWIRE / June 4, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that effective May 27, 2021, the Company granted nonstatutory stock options for the purchase of up to 225,000 shares of the Company's common stock to a new employee, as an inducement award under the Company's 2020 Inducement Plan.

    View More →
  • REMINDER: Innovators with Jane King Webcast Interview with Jaguar Health CEO Lisa Conte & Dragon SPAC Founding Sponsor Josh Mailman to Take Place Thursday, June 3, 2021 at 8:30 AM Eastern

    Registration link for webcast appears belowSAN FRANCISCO, CA / ACCESSWIRE / June 2, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") issued a reminder today that an Innovators with Jane King webcast interview with Jaguar CEO Lisa Conte & Dragon SPAC S.

    View More →
  • Jaguar Health & Dragon SPAC Announce Initial Funding of US$10.8 Million into Dragon SPAC

    , named target of Dragon SPAC, provides update on plan to pursue conditional marketing authorization for crofelemer in EUEquita Group S., a leading Italian based investment bank, advising Dragon SPAC; Cantor Fitzgerald & Co.

    View More →
  • Napo EU S.p.A., Jaguar Health’s Italian Subsidiary, Provides Updates on Plans to Pursue Conditional Marketing Authorization in the EU

    Jaguar & Dragon SPAC announce initial funding of $10.8 million into Dragon SPACNapo EU to focus initially on conditional approval for an important orphan indication, short bowel syndrome (SBS), a condition leading to intestinal failureInnovators with Jane King webcast interview with Jaguar CEO Lisa Conte & Dragon SPAC founding sponsor Josh Mailman to take place Thursday, June 3rd at 8:30 AM EasternRegistration link for webcast appears belowEquita Group S.

    View More →
  • Napo Pharmaceuticals, Jaguar Health’s Subsidiary, Bolsters Management Team with Appointment of Darlene Horton, M.D. as Chief Medical Officer

    SAN FRANCISCO, CA / ACCESSWIRE / May 26, 2021 / Napo Pharmaceuticals Inc., the wholly-owned subsidiary of Jaguar Health, Inc.

    View More →
  • Jaguar Health and Napo Pharmaceuticals Provide Key Findings from Cancer-related Diarrhea Abstracts Submitted to ASCO for June 2021 Annual Meeting

    SAN FRANCISCO, CA / ACCESSWIRE / May 20, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the highlights of the abstract regarding patient outcomes associated with cancer-related diarrhea ("CRD") by Napo Pharmaceuticals, Inc.

    View More →
  • Jaguar Animal Health (JAGX) Q1 2021 Earnings Call Transcript

    Before I turn the call over to management, I would like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of product, the impact of competitive products and pricing, industry trends and product and technology initiatives, including products in the development stage which may not achieve scientific objectives or meet stringent regulatory requirements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. While management believes that its assumptions, expectations, and projections are reasonable in view of current available information, you are cautioned not to place undue reliance on these forward-looking statements.

    View More →
  • Jaguar Health Announces the Launch of a New Social Media Channel Dedicated to Reaching the Growing Jaguar Health Community

    Newly created Jaguar Health Community Instagram page introduces jaguar-themed contestSAN FRANCISCO, CA / ACCESSWIRE / May 19, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company recently launched a new social media channel for stakeholders and the Company's growing community of followers.

    View More →
  • Jaguar Health Provides Updates on Canalevia (Crofelemer), the First Plant-based Prescription Medicine Under Development for Chemotherapy-induced Diarrhea in Dogs and Exercise-induced Diarrhea in Dogs

    Canalevia would be first and only FDA-approved plant-based medicine for dogs that suffer from diarrhea during chemotherapyCanalevia will be available by fourth quarter 2021, if conditionally approvedSAN FRANCISCO, CA / ACCESSWIRE / May 18, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided updates regarding the development program for the Company's oral plant-based drug candidate Canalevia™ (crofelemer delayed-release tablets) to treat chemotherapy-induced diarrhea (CID) in dogs and exercise-induced diarrhea (EID) in dogs.

    View More →
  • Jaguar Health, Inc. Reports 2021 First Quarter Financial Results

    First quarter 2021 Mytesi gross sales and net sales were approximately $4.2 million, increases of 250% and 43%, respectivelyCompany to host investor webcast Monday, May 17th at 8:30 a.

    View More →
  • Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, June 11, 2021 and Encourages All Shareholders to Vote

    Based on a preliminary review of votes cast, over 80% have voted in favor of Proposals 2, 3, 4 & 6 Meeting scheduled to reconvene June 11, 2021 at 8:30 AM Pacific Standard Time to provide time to reach quorumReminder: Jaguar to host investor webcast Monday, May 17th at 8:30 AM Eastern Time regarding Q1 2021 financials & business updatesSAN FRANCISCO, CA / ACCESSWIRE / May 14, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that its Annual Meeting of Stockholders held on May 13, 2021 (the "Annual Meeting") was adjourned due to a lack of quorum.

    View More →
  • Jaguar Health to Host Investor Webcast Monday, May 17th at 8:30 AM Eastern Time Regarding Q1 2021 Financials & Business Updates

    Webcast registration link appears belowCompany plans to file Q1 2021 10-Q on May 17, 2021 SAN FRANCISCO, CA / ACCESSWIRE / May 11, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Company management will host a webcast on Monday, May 17, 2021 at 8:30 a.

    View More →
  • Jaguar Health Announces $10.8 Million Registered Direct Offering for the Benefit of Napo EU Business Plan

    Company terminates at-the-market (ATM) financing programSAN FRANCISCO, CA / ACCESSWIRE / April 29, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced it has entered into a securities purchase agreement (the "Transaction") with North American institutional investors for the purchase and sale of 7,647,000 shares of common stock for gross proceeds of approximately $10.

    View More →
  • Jaguar Health and Napo Pharmaceuticals Announce Title of Abstract Regarding Patient Outcomes Associated with Cancer Therapy-Related Diarrhea Accepted for Poster Presentation at the American Society of Clinical Oncology 2021 Annual Meeting

    SAN FRANCISCO, CA / ACCESSWIRE / April 29, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced the title of the abstract regarding patient outcomes associated with cancer therapy-related diarrhea ("CTD") by Napo Pharmaceuticals, Inc.

    View More →
  • REMINDER FROM JAGUAR HEALTH: Innovators with Jane King Webcast Interview to Take Place Friday, April 23, 2021 at 8:30 AM Eastern to Provide a Business Overview of Napo EU S.p.A., Jaguar’s New Italian Subsidiary

    Registration link for webcast interview appears belowSAN FRANCISCO, CA / ACCESSWIRE / April 21, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") issued a reminder today about the Innovators with Jane King interview of Lisa Conte, the Company's founder, president, and CEO, and Josh Mailman, the lead sponsor of the Dragon special purpose acquisition company (the "Dragon SPAC"), that will air during a webcast this Friday, April 23, 2021, at 8:30 AM Eastern to provide a business overview of Napo EU S.

    View More →
  • Jaguar Health Announces Innovators with Jane King Webcast Interview to Take Place Friday, April 23, 2021 at 8:30 AM Eastern to Provide a Business Overview of Napo EU S.p.A., the Company's New Italian Subsidiary

    Registration link for webcast interview appears belowCompany premiers Napo EU's new logo and branding, now live on Napoeu.com website SAN FRANCISCO, CA / ACCESSWIRE / April 19, 2021 / Jaguar Health, Inc.

    View More →
  • 7 Reddit Penny Stocks to Buy for a Biotech Boom

    Penny stocks across all sectors have been popular with investors active on Reddit’s r/WallStreetBets subreddit. But, one area, in particular, they’ve found many of their favorites has been in the biotech space. Not only a lot of penny, or low-priced stocks, are in this industry. The high-risk, high-potential return nature of biotech investing makes it no surprise retail speculators online are active in this area. Earlier this year, Reddit investors sent many low-priced biotech names “to the moon.” But, in recent weeks, many of these popular names have pulled back from their highs. For some, this is justified. There was little going on to justify their inflated valuations. For others, though, there’s more in their corner than just online hype. For biotech names, things can be very make-or-break. News of Food and Drug Administration (FDA) approval can turn a stock parabolic. But, one hiccup, misstep, or stumble can send a biotech stock down 50%, 60%, even 75% in a day.InvestorPlace - Stock Market News, Stock Advice & Trading Tips In short, this isn’t an area you should bet the ranch on one opportunity. Yet, for those with an adequate risk appetite, and the discipline to size positions? You can find many opportunities where the potential for gains more than makes up for the high risk. 10 Stocks to Buy for Your $5K Robinhood Portfolio So, which biotech penny stocks, popular with the Reddit set, offer such opportunity? Consider these seven as ones with potential to live up to online enthusiasm: 180 Life Sciences (NASDAQ:ATNF) Citius Pharmaceuticals (NASDAQ:CTXR) Jaguar Health (NASDAQ:JAGX) Ocugen (NASDAQ:OCGN) Savara (NASDAQ:SVRA) Timber Pharmaceuticals (NYSEAMERICAN:TMBR) Zosano Pharma (NASDAQ:ZSAN) Penny Stocks: 180 Life Sciences (ATNF) Source: Iryna Imago / Shutterstock.com With its epic run over the past month, ATNF stock has rallied far above penny-stock status (less than $5 per share). But, with pulling back to single-digit prices, you may want to keep it on your radar. What’s been behind the dramatically increased interest in 180 Life Sciences? Increased awareness of the potential of its therapeutic candidates by Reddit investors helped to fuel its initial surge starting in March. But, recent news of insider buying helped this former penny stock rally above $10 per share. So, why could shares pull back? And, why may it be a great opportunity at lower prices? Namely, its possibility in bringing fibrosis and anti-TNF (anti-tumor necrosis factor) therapies to market. However, recent developments have been minimal. In turn, it’s hard to tell whether shares can continue to climb. Or, if there’s risk of a selloff just around the corner. Yet, if the company down the road makes progress with its pipeline, such news could give shares yet another boost. With Reddit investors onto something here, keep ATNF stock on your radar. Citius Pharmaceuticals (CTXR) Source: Shutterstock As has been par for the course with Reddit penny stocks, CTXR stock peaked during February’s madness. But, while news of a dilutive capital raise, along with fading enthusiasm for meme stocks, has resulted in shares pulling back nearly 39% off their highs, it may be premature to say it’s time to throw in the towel. What’s the “story” behind Citius? As InvestorPlace’s Louis Navellier broke it down March 22, the company has three promising candidates in its pipeline. These are blood infection treatment Mino-Lok, Mino-Wrap, a product to be used for preventing infections that can occur during breast reconstruction surgery, and Halo-Lido, an anti-inflammatory treatment for hemorrhoids. As discussed in its March 2021 investor presentation, Mino-Wrap and Halo-Lido have yet to move far down the pipeline. But, Mino-Lok is already in Phase 3 clinical trials. Further news signaling Mino-Lok’s eventual approval and commercialization will definitely be a needle-mover for CTXR stock. With a total addressable market of $1.5 billion, the financial rewards for this company could be massive. 10 Stocks to Buy for Your $5K Robinhood Portfolio While down from its February highs, shares at today’s prices (around $1.66 per share) are still up big from the start of 2020 (when it traded for around $1 per share). Yet, given the possible game-changers in its pipeline, consider it well worth the risk. Jaguar Health (JAGX) Source: Spyro the Dragon/Shutterstock.com What’s the story with JAGX stock, once one of the most popular penny stocks among Reddit investors? It’s a biotech name with a novel coronavirus catalyst. No, it doesn’t have a vaccine in its pipeline. As I discussed back in February, the company is one of many names focused on chronic Covid treatment. How? Via its Mytesi treatment. Mytesi was first created for HIV/AIDS patients with antiretroviral therapy-related chronic diarrhea. But, it may have potential as a treatment for those suffering from long-term Covid-19 symptoms. Before, Reddit investors got carried away with JAGX stock. Its valuation rose to levels way beyond the possible Covid-related upside. But, now, the stock has fallen by more than 50%. That’s not to say the stock is cheap, by any means. But, following its selloff, any positive news on Mytesi may be enough to fuel a rebound. Jaguar Health has other promising candidates in its pipeline, including its Canalevia chemotherapy-induced diarrhea treatment for dogs. Yet, so much riding on Mytesti, exercise some caution. Any positive news could send it surging again. But, negative developments could send it back to prices well below $1 per share. Penny Stocks: Ocugen (OCGN) Source: Shutterstock Like with ATMF stock, OCGN stock is a former penny stock that’s moved beyond $5 per share. Hype with this Covid-19 vaccine play may be off-the-charts. But, even with its vaccine contender a long shot, that doesn’t mean shares could again make another rip higher. How so? While it’s a bit late to the party, with Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE) now widely distributing their vaccines, Ocugen may find success, as it tries to bring India-based Bharat Biotech’s Covaxin candidate to the United States. With U.S. Government pausing distribution of Johnson & Johnson’s (NYSE:JNJ) vaccine, there may be opportunity for some of the also-rans to get emergency use authorization (EUA). Initial news of the Covaxin deal sent it from around $1 per share to more than $19 per share. But, the stock has since sold off. So far, the JNJ vaccine news hasn’t done much to renew confidence in Ocugen’s prospects. 10 Stocks to Buy for Your $5K Robinhood Portfolio Yet, with this recent news possibly paving the way for this long-shot Covid-19 vaccine contender to get U.S. regulatory approval, it may be worth it to take a calculated bet on OCGN at today’s prices. Savara (SVRA) Source: Shutterstock Since moving from around $1.20 per share to around $1.80 per share, Savara stock has traded sideways. But, this developer of respiratory therapies may have a shot of breaking out to substantially higher price levels. At least, that’s the view of Oppenheimer’s Francois Brisebois, who last month initiated coverage on the stock. Giving SVRA stock the equivalent of a “buy” rating, and a price target of $4 per share, the analyst is bullish on the prospects of the company’s Molgradex candidate. This candidate is a treatment for aPAP, or autoimmune pulmonary alveolar proteinosis. So, why haven’t investors been more excited about this stock? The on-the-fence view of Savara may have to do with its recent $130 million secondary offering. This transaction raised much-needed capital to sustain its operations. But, it’s come at the cost of heavy shareholder dilution. This dilution could limit to what extent SVRA stock gains if Molgradex becomes a marketable product. Even so, with the high confidence this flagship candidate will live up to expectations, buying this stock, as investors remain on the fence, could be a profitable move in hindsight. Timber Pharmaceuticals (TMBR) Source: Shutterstock Timber Pharmaceuticals is yet another of the Reddit penny stocks that’s been a roller-coaster ride so far this year. Shares in this developer of treatments for rare dermatologic diseases started the year off trading for around 80 cents per share. But, at the height of meme stock/Reddit stock madness, shares briefly hit prices above $3 per share. But, except for another brief spike above $3 per share in March, shares have since fallen back to around $1.50 per share. As much of its Reddit hype has begun to fade, focus now returns to the underlying fundamentals of TMBR stock. So, does Timber have potential to become a long-term winner? Or, will shares pull back to prior levels? Admittedly, it’s too hard to tell right now. With most of its pipeline still in Phase 2 trials, it may take some time to determine whether it has a marketable product in its hands. 10 Stocks to Buy for Your $5K Robinhood Portfolio But, biotech penny stocks remain popular with retail traders. This may be enough to keep TMBR stock steady. News related to its BPX-01 and BPX-04 candidates, currently in late stage clinical trials, could help fuel another rally back to $3 per share and above. Approach it cautiously, but this remains a Reddit biotech play to keep an eye on. Penny Stocks: Zosano Pharma (ZSAN) Source: Shutterstock Zosano Pharma, which is developing a transdermal microneedle treatment for migraines called Qtrypta, grabbed the attention of Reddit traders earlier this year. Like many other biotech names, shares saw a dramatic uptick in February, followed by an extended cooling off period. Today, ZSAN stock is down more than 65% off its highs. But, given shares were trading for around 60 cents per share at the end of 2020, at today’s prices ($1 per share) it’s still up substantially. That may leave some worried shares have more room to fall, as enthusiasm continues to cool. But, to some extent, the story’s improved with Zosano. The company has made some progress obtaining approval for Qtrypta. Last fall, the FDA rejected Zozano’s initial application for Qtrypta. But, it’s not giving up on its flagship candidate. With plans for a new study, the company has high hopes the second go-around with the FDA will be a success. Yet, this slight improvement in its prospects may already be factored into the stock price. More positive news will likely produce another outsized rally for ZSAN stock. It’s still a gamble, but it may be one that pays off in the end. On the date of publication, Thomas Niel did not have (either directly or indirectly) any positions in the securities mentioned in this article. Thomas Niel, a contributor to InvestorPlace, has written single stock analysis since 2016. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesn’t matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner Stock Prodigy Who Found NIO at $2… Says Buy THIS Now The post 7 Reddit Penny Stocks to Buy for a Biotech Boom appeared first on InvestorPlace.

    View More →